Bloomberg
Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Monday, November 16, 2026
Eli Lilly & Co. agreed to acquire Calytrix Bio Inc. for up to 1.5 billion dollars. The deal is part of Lilly's acquisitions totaling 32 billion dollars in 2026, focused on expanding its cancer and immunology portfolios. Calytrix Bio is a privately held company.
Original reporting:
